<DOC>
	<DOCNO>NCT01005862</DOCNO>
	<brief_summary>The primary goal study evaluate effect PF-04360365 clearance ABETA CSF ( cerebrospinal fluid ) patient mild Alzheimer 's disease healthy volunteer . Additionally , study assess pharmacokinetics PF-04360365 , pharmacokinetic pharmacodynamic relationship plasma CSF safety tolerability single dose PF-04360365 administer patient Alzheimer 's disease healthy volunteer .</brief_summary>
	<brief_title>Effect PF-04360365 On ABETA In Patients With Alzheimer 's Disease And Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Males female nonchildbearing potential ( age 50 Alzheimer 's disease patient ; 2145 healthy volunteer ) For patient Alzheimer 's Disease : Diagnosis probable Alzheimer 's disease , consistent criterion National Institute Neurological Communicable Disease Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Diagnostic Statistical Manual Mental Disorders ( DSM IV ) Minimental status exam score great equal 20 RosenModified Hachinski Ischemia Score &lt; = 4 On stable dose background cholinesterase inhibitor memantine least 3 month prior enrollment Diagnosis history demential neurodegenerative disorder Diagnosis history clinically significant cerebrovascular disease Specific find magnetic resonance imaging ( MRI ) ; cortical infarct , micro hemorrhage , multiple white matter lacunes , extensive white matter abnormality History autoimmune disorder History allergic anaphylactic reaction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Alzheimer 's disease antibody leucine ABeta</keyword>
</DOC>